Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Minimal access surgery and urological malignancies

AORTIC

Published: 21 Dec 2009

Views: 12966

Rating:

Save

Dr Andre van der Merwe - Stellenbosch University, South Africa

Dr van de Merwe talks about the success of a workshop on keyhole surgery for tumours and the issue of urological malignancies in southern Africa.

This filming was supported by an unrestricted grant from Pfizer Oncology.

Related Videos

Baseline characteristics of patients with PSMA-PET–positive and –negative...

Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany

Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk BCR after radical RP ( Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany )

Radiation therapy after radical surgery in prostate cancer

Dr Roberto Paz - Oncosalud - AUNA, Lima, Peru

Radiation therapy after radical surgery in prostate cancer ( Dr Roberto Paz - Oncosalud - AUNA, Lima, Peru )

ASCO 2023: Latest in PARP inhibitors in prostate cancer

Prof Rana McKay, Dr Friederike Schlurmann, Prof Gunhild von Amsberg

ASCO 2023: Latest in PARP inhibitors in prostate cancer ( Prof Rana McKay, Dr Friederike Schlurmann, Prof Gunhild von Amsberg )

Extended lymph node removal does not benefit patients with clinically localised...

Dr Seth Lerner - Baylor College of Medicine, Houston, USA

Extended lymph node removal does not benefit patients with clinically localised muscle-invasive bladder cancer ( Dr Seth Lerner - Baylor College of Medicine, Houston, USA )

Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free...

Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany

Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival via PSMA-radioguided surgery ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )

Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable...

Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany

Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )

Surgical technique remains the most important factor associated with recovery...

Dr Rafael Sanchez-Salas - McGill University Health Center, Montreal, Canada

Surgical technique remains the most important factor associated with recovery of urinary continence after radical prostatectomy ( Dr Rafael Sanchez-Salas - McGill University Health Center, Montreal, Canada )

ASCO GU 2023: Latest updates in mRCC

Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor...

ASCO GU 2023: Latest updates in mRCC ( Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor Grünwald and Prof Toni Choueiri )

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

More from ecancer